Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States by Gandra, S.R. et al.
Address for correspondence:
Shravanthi R. Gandra, PhD, MBA
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320
shravanthi.gandra@amgen.com
Quality and Outcomes
Cost-Effectiveness of LDL-C Lowering
With Evolocumab in Patients With High
Cardiovascular Risk in the United States
Shravanthi R. Gandra, PhD, MBA; Guillermo Villa, PhD; Gregg C. Fonarow, MD; Mickael
Lothgren, PhD; Peter Lindgren, PhD; Ransi Somaratne, MD, MBA; Ben van Hout, PhD
Department of Global Health Economics (Gandra), Department of Clinical Development
(Somaratne), Amgen Inc., Thousand Oaks, California; Economic Modeling Center (Villa,
Lothgren), Amgen (Europe) GmbH, Zug, Switzerland; Ahmanson-UCLA Cardiomyopathy Center,
Division of Cardiology (Fonarow), Geffen–UCLA School of Medicine, Los Angeles, California;
Department of Health Economics (Lindgren), the Swedish Institute for Health Economics, Lund,
Sweden; Department of Learning, Informatics, Management and Ethics (Lindgren), Karolinska
Institute, Stockholm, Sweden; Department of Health Economics (van Hout), University of
Shefﬁeld, Shefﬁeld, United Kingdom
Randomized trials have shown marked reductions in low-density lipoprotein cholesterol (LDL-C), a risk factor
for cardiovascular disease (CVD), when evolocumab is administered. We hypothesized that evolocumab added
to standard of care (SOC) vs SOC alone is cost-effective in the treatment of patients with heterozygous
familial hypercholesterolemia (HeFH) or atherosclerotic CVD (ASCVD) with or without statin intolerance and
LDL-C >100mg/dL. Using a Markov cohort state transition model, primary and recurrent CVD event rates
were predicted considering population-speciﬁc trial-based mean risk factors and calibrated against observed
rates in the real world. The LDL-C–lowering effect from population-speciﬁc phase 3 randomized studies
for evolocumab was used together with estimated LDL-C–lowering effect on CVD event rates per 38.67-
mg/dL LDL-C lowering from a statin-trial meta-analysis. Costs and utilities were included from published
sources. Evolocumab treatment was associated with both increased cost and improved quality-adjusted life-
years (QALY): HeFH (incremental cost: US$153 289, incremental QALY: 2.02, incremental cost-effectiveness
ratio: US$75 863/QALY); ASCVD (US$158 307, 1.12, US$141 699/QALY); and ASCVD with statin intolerance
(US$136 903, 1.36, US$100 309/QALY). Evolocumab met both the American College of Cardiology/American
Heart Association (ACC/AHA) and World Health Organization (WHO) thresholds in each population evaluated.
Sensitivity and scenario analyses conﬁrmed that model results were robust to changes in model parameters.
Among patients with HeFH and ASCVD with or without statin intolerance, evolocumab added to SOC may
provide a cost-effective treatment option for lowering LDL-C using ACC/AHA intermediate/high value andWHO
cost-effectiveness thresholds. More deﬁnitive information on the clinical and economic value of evolocumab
will be available from the forthcoming CVD outcomes study.
Introduction
Approximately 86 million people in the United States have
cardiovascular disease (CVD); it accounts for 1 out of every 3
deaths and remains the leading cause of death.1 Despite the
widespread use of statins, the economic burden associated
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with CVD is onerous, with >US$650 billion spent on CVD-
related costs annually in theUnited States.1,2 These costs are
projected to nearly double by 2030.1 The cost-effectiveness
of new therapies has become increasingly important as
healthcare costs continue to rise and information about
making tradeoffs becomes critical.
Low-density lipoprotein cholesterol (LDL-C) has been
established as a modifiable risk factor for CVD. A
meta-analysis conducted by the Cholesterol Treatment
Trialists’ Collaboration (CTTC) found that every 38.67-
mg/dL (1mmol/L) reduction in LDL-C with statin therapy
results in a 21% (statins vs control) and 28% (more vs less
statins) reduction in rates of any major CVD event across 26
randomized trials.3 Results from the Improved Reduction of
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Outcomes: Vytorin Efficacy International Trial (IMPROVE-
IT) evaluating ezetimibe, a cholesterol absorption inhibitor,
in reducingmajor CVD events suggested the CTTCfindings
that lowering LDL-C with a nonstatin reduces the risk for a
CVD event.4
Many high-risk patients cannot adequately reduce LDL-C
levels despite intensive statin therapy. For these patients,
addition of available treatment options to the standard
of care (SOC) is reasonable.5 Proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibition has emerged as a
new therapy for lowering LDL-C. The results of the phase 3
trials conducted on evolocumab, a recently approved PCSK9
inhibitor, showed that the addition of evolocumab to SOC
led to average reductions in LDL-C levels of 50% to 70%
in patients with heterozygous familial hypercholesterolemia
(HeFH) or atheroscleroticCVD(ASCVD),6,7 aswell as statin
intolerance.8 A cardiovascular outcomes trial of evolocumab
is ongoing (NCT01764633), but exploratory data from 2
open-label studies suggest a clinically significant reduction
in cardiovascular risk with evolocumab.9
It is important to assess the economic value of evolocumab
to payers in the United States. Economic modeling can
provide US payers with information about the value of LDL-
C lowering with evolocumab. We used an economic model
to assess the cost-effectiveness of evolocumab added to SOC
vs SOC alone in patients with hypercholesterolemia.
Methods
A Markov cohort state transition model considering a US
payer perspective and a lifetime horizon and treatment
duration was used to assess the cost-effectiveness of
evolocumab added to SOC vs SOC alone in 3 distinct
populations whose trial data are available: (1) Patients
with HeFH; (2) patients with ASCVD, defined as ≥1 prior
CVD event, without statin intolerance; and (3) patients with
ASCVD with statin intolerance.
Each population was modeled considering patients
with baseline LDL-C >100mg/dL (Table 1). The SOC
varied depending on the population: HeFH, high-intensity
statins; ASCVDwithout statin intolerance,medium-intensity
and high-intensity statins (with statin intolerance, no
treatment).5 The outcomes of the model were CVD event
rates, cost per life-year (LY) gained, and cost per quality-
adjusted life-year (QALY). The model was built in Microsoft
Excel 2010 (Microsoft Corp., Redmond, WA).
Model Structure
The health states included in the model (Figure 1) were
no-CVD, established CVD (ECVD), acute coronary syn-
drome (ACS), post-ACS, ischemic stroke (IS), post-IS, heart
failure (HF), post-HF, coronary heart disease (CHD) death,
IS death, and non-CVD death. The CVD events included
under EVCD were transient ischemic attack, peripheral
vascular disease, stable angina, carotid stenosis, revascu-
larization in the absence of myocardial infarction (MI),
and abdominal aortic aneurysm. Acute coronary syndrome
included MI and unstable angina. Patients could enter the
model at no-CVD or at dedicated prior-CVD health states
such as post-ACS, post-IS, post-HF, or ECVD. Revascu-
larization was included as a procedure, not as a separate
Table 1. PatientDemographics andBaselineCharacteristics byPopulation
HeFH,
n= 324
ASCVD,
n= 351
ASCVD
(Statin-Intolerant),
n= 115
Age, mean, y 51.2 62.1 64.0
Female sex, % patients 42 34 37
BMI, kg/m2 28.0 29.5 28.4
BMI<20 kg/m2 2 0 2
Type 2 DMa, % patients 26 26 26
LDL-C, mean, mg/dL 156.5 141.3 189.4
HDL-C, mean, mg/dL 51.2 50.7 50.7
TG, mean, mg/dL 125.7 155.9 169.5
Therapy for HTN % patients 33 62 77
SBP, mm Hg 125.8 129.6 133.6
Secondary prevention % patients 39 100 100
No. of vascular bedsb, mean 1.2120 1.2120 1.2120
AFb, % patients 11.7 11.7 11.7
Smoking, % patients 16 12 6
ASA use at baseline, % patients 39 55 69
Proportion of secondary
prevention, % patients
39 100 100
10-year risk of ≥1 CVD event % 58 44 43
Initial health statec, % patients
ECVD 61 47 54
Post-ACS 26 29 32
Post-IS 2 5 7
Post-HF 1 8 2
Combination health states 11 15 5
Abbreviations: ACS, acute coronary syndrome; AF, atrial ﬁbrillation;
ASA, aspirin; ASCVD, atherosclerotic cardiovascular disease; BMI,
body mass index; CVD, cardiovascular disease; ECVD, established
cardiovascular disease; DM, diabetes mellitus; HeFH, heterozygous
familial hypercholesterolemia; HF, heart failure; HDL-C, high-density
lipoprotein cholesterol; HTN, hypertension; IS, ischemic stroke; LDL-C,
low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG,
triglycerides.
aImputed as 25.9% based on real-world US claims data,23 because the
evolocumab clinical studies had a much lower proportion of patients
with type 2 DM than the US population. bImputed for all populations
based on Wilson et al13 because data were not available in the study
databases. cPercentages may not add up to 100% due to rounding.
health-state, and the costs of revascularizationwere included
for a proportion of patients in the ECVD, ACS, and post-ACS
health states according to published data.10,11
Combined health states (see Supporting Information,
Table 1, in the online version of this article) were created to
retain memory of prior events in the model. The following
assumptions for combined health states’ costs, utilities, and
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Figure 1. Evolocumab economic model structure. Abbreviations: ACS, acute coronary syndrome; CHD, coronary heart disease; CVD, cardiovascular disease;
ECVD, established cardiovascular disease; HF, heart failure; IS, ischemic stroke.
risks were considered: the highest of the costs for the
individual health states involved was used as the cost for
a combined health state. The costs were not added up,
because addition may overestimate the costs. The lowest
utility of the individual health states was used as the utility of
a combinedhealth state. Thehighest risk from the individual
health states to a specific event was used as the risk of the
combined health state to that specific event.
Model Inputs
Baseline Risks: Published risk-prediction engines12,13 for
primary (Framingham) and recurrent (Reduction of
Atherothrombosis for Continued Health [REACH]) CVD
events for SOC alone, calibrated using rate ratios to reflect
real-world scenarios, were used to estimate the baseline
CVD risk. Calibration ensured that the model predicted the
relevant events considered and that it reflected the risk of
a much higher-risk population than the one used to derive
the equations originally. The rate ratios were determined by
the division of the number of CVD events in an analysis of
real-world observational data14,15 and the events predicted
by the risk engines,12,13 controlling for individual patient
characteristics (such as age, systolic blood pressure, and
diabetes status) for the higher-risk population indicated
for PCSK9 inhibitor treatment. We used an analysis of real-
world long-termUKdata for theASCVDpopulation, because
US claims data are usually limited to <10 years owing to
patients switching for changes in employment. The HeFH
population in the United States is not well characterized
or studied, so we used a study from Europe,16 where the
literature on this topic is available and reliable. Average
calibration factors for the ASCVD populations ranged from
2.35 to 5.10 (acute) and 0.92 to 2.56 (long term). Patients
withHeFHhave a higher baselineCVDrisk than theASCVD
population due to longer exposures of higher levels of LDL-
C. Therefore, a different rate ratio (7.1; 95% confidence
interval [CI]: 5.7-8.7), based on the results of a Danish
familial hypercholesterolemia study,16 was used.12,13 The
resulting calibration factors led to an estimated 10-year risk
of ≥1 CVD events of 51% for HeFH and 44% for ASCVD (51%
with statin intolerance).
Treatment Efﬁcacy: The predicted effectiveness of
evolocumab on reducing CVD event rates was derived
from the relative LDL-C reduction from baseline to week
12 observed among evolocumab-treated patients in the
clinical program: HeFH,17 61% (95% CI: 55%-67%); ASCVD,17
71% (61%-81%); and ASCVD with statin intolerance,8
56% (52%-60%). The CTTC meta-analysis, analyzing the
cardiovascular rate reduction of statin use, was considered.3
The CTTC rate ratios for CVD events were applied to the
rates of events predicted (Table 2).
Mortality: The 2010 US life tables18 were used to predict
all-cause mortality by age and sex. CVD mortality was
predicted separately from non-CVD mortality. Non-CVD
mortality was further assumed to be the same as that of the
general population in the US life tables.
Utility: Baseline utility, where 0 indicates death and 1
indicates full health, applied to the no-CVD health state, was
estimated as 0.824 for the US population age >45 years.19
The utilities for other health states (Table 2) were based
on the results of a time tradeoff study.20 The 1-year time
tradeoffmethodwas used to evaluate the acute health states,
with the 10-year time tradeoff method used for the chronic
health states (Table 2).
Costs: The annual US wholesale acquisition price of
evolocumab (US$14 139) was used in the cost-effectiveness
analysis, and possible discounts were not accounted for
in the model. Statin costs were based on published data
(average of RedBook prices and themarket share of generic
simvastatin and atorvastatin),21 andmedication costs did not
include monitoring or management. Costs associated with
CVDhealth stateswere obtained throughUSclaimsdata22,23
(Table 2) with a 3-year horizon. The analysis included the
acute and short-term costs for the first year and the long-
term costs for years 2 and 3. In the absence of information,
non-CVD death events were assumed to not incur any
costs.24 Indirect costs were not included in the base case or
scenarios in accordance with the payer perspective used in
the analyses.
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Table 2. Rate ratio of CVD Events per 38.67mg/dL of LDL-C Reduction,
Costs, and Utility Values for Health States
Item Rate Ratio (CI)a Utility (SD)b
Direct Cost,
$US (SE)c
ECVD 0.71 (0.58-0.87) 8096 (307)
ACSd 0.71 (0.58-0.87) 0.672 (0.340) 49 604 (693)
IS 0.69 (0.50-0.95) 0.327 (0.456) 44 007 (1042)
HFe 0.71 (0.58-0.87) 0.602 (0.456) 45 514 (932)
Post-ACSd NA 0.824 (0.174) 8096 (307)
Post-IS NA 0.524 (0.377) 8396 (604)
Post-HF NA 0.571 (0.322) 17 562 (732)
CHD death 0.80 (0.74-0.87) 72 892 (550)
IS death 1 (assumption) 72 892 (550)
Revascularizationf 0.66 (0.60-0.73) 56 556 (448)
Abbreviations: ACS, acute coronary syndrome; CABG, coronary
artery bypass grafting; CHD, coronary heart disease; CI, conﬁdence
interval; CTTC, Cholesterol Treatment Trialists’ Collaboration; CVD,
cardiovascular disease; ECVD, established cardiovascular disease;
HF, heart failure; IS, ischemic stroke; LDL-C, low-density lipoprotein
cholesterol; MI, myocardial infarction; NA, not applicable; PCI,
percutaneous coronary intervention; SD, standard deviation; SE,
standard error; UA, unstable angina; USD, United States dollars.
aCIs are 99% except for revascularization, which is 95%. Source: CTTC.3
ECVD and HF health states were assumed to be equivalent to ACS. IS
death was assumed to have a rate ratio of 1, because the rate ratio
per 38.67-mg/dL LDL-C reduction was not statistically signiﬁcant (1.04;
99% CI: 0.77-1.41). bIn utilities, 0 represents death and 1 represents
perfect health. cSource: US Claims Data.22,23 dACS was deﬁned as UA
or MI. eFor transitions from HF to HF and post-HF to HF, the clinical
beneﬁt was not applied, reﬂecting results of statin trials in which LDL-C
reduction did not signiﬁcantly reduce primary composite endpoints in
patients with recurrent HF.38 fRevascularization was deﬁned as PCI or
CABG.
In evolocumab phase 3 studies, there was a low rate of
muscle-related symptoms reported in the statin-intolerant
population8 but no notable differences in the adverse
event profiles between evolocumab-treated patients and the
placebo-treated patients in the HeFH population6 or the
placebo-treated or ezetimibe-treated patients in the ASCVD
population.7 Based on these findings, the incidence, cost,
and impact on health-related quality of life associated with
adverse events were not included in the model for any
comparator.
Analyses
Base-Case Analysis: Costs, LYs, and QALYs were each
discounted at 3%, as recommended by the US Panel on
Cost-Effectiveness in Health and Medicine.25
As there is no well-defined cost-effectiveness threshold
in the US, the predicted incremental cost-effectiveness
ratios (ICERs) were compared with cost-effectiveness
thresholds26 from the World Health Organization (WHO)
and the statement on level of value27 from the American
College of Cardiology/American Heart Association
(ACC/AHA), although some estimates for willingness
to pay are much higher (eg, US$300 000/QALY).28
The WHO thresholds were based on 2014 US gross
domestic product per capita (US$54 629.50, World Bank):
highly cost-effective, <US$55 000/QALY; cost-effective,
US$55 000 to US$165 000/QALY; and not cost-effective,
>US$165 000/QALY gained. The ACC/AHA thresholds
were based on the level of value to society: high,
<US$50 000/QALY gained; intermediate, US$50 000
to<US$150 000/QALY; and low, ≥US$150 000/QALY.
Sensitivity Analyses: To assess the robustness of our
results to changes in the input parameters, both univariate
deterministic and multivariate probabilistic sensitivity
analyses were conducted. When possible, 95% CIs were
considered to define the lower and upper bounds and
to parameterize the probability distributions. Model
inputs included in the sensitivity analyses were LDL-C
relative reductions, reductions in rates of CVD events per
38.67-mg/dL LDL-C reduction, health state costs, and utility
values.
The relative reduction in LDL-C and the rate reduction in
CVD events per 38.67-mg/dL LDL-C reduction were varied
by the CIs reported in the clinical trials and the CTTCmeta-
analysis.3 The sensitivity analyses of baseline CVD rate
calibration factors were set to upper and lower CI bounds
from a literature analysis for HeFH patients29 and registry
data for ASCVD patients.30 For health state costs and utility
values, the values were varied based on previously reported
CIs for acute and long-term health states.19,20
Probabilistic sensitivity analysis was conducted for LDL-C
relative reductions, reduction in rates of CVD events, and
health state costs and utility values. The base-case analysis
used the recommended distributions by Briggs et al31
(β, LDL-C relative reductions; lognormal, rate reduction
per 38.67-mg/dL LDL-C reduction; γ, health state costs;
β, health state utility values). Model parameters were
randomly sampled 1000 times. The probability of the new
intervention being cost-effective for different willingness to
pay thresholds was then presented in the cost-effectiveness
acceptability curve.
Scenario Analyses: Scenario analyses included reduction in
rates of CVDevents observed in the evolocumabOpen-Label
Study of Long-term Evaluation Against LDL Cholesterol
(OSLER) studies,9 no LDL-C–lowering effect on rates of
HF, compliance from the OSLER studies,9 and alternate
discount rates. A separate scenario analysis assessed
price thresholds at which evolocumab met the ACC/AHA
intermediate level-of-value and WHO cost-effectiveness
thresholds.
Results
Evolocumab use was associated with a relative reduction in
nonfatal CVD event rates ranging from 36% to 61% and a 25%
to 43% reduction in CHD death rates according to the model
(Table 3). The initial HeFH rate ratio of 7.1 translated into
HeFH patients being predicted to have 3.7× more events
over a lifetimehorizon than non-HeFHpatientswith a similar
risk profile. The incremental costs of evolocumab added to
SOC over SOC alone in theHeFH, ASCVD, and ASCVDwith
statin intolerance populationswereUS$153 289,US$158 307,
and US$136 903, respectively. These populations gained
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Table 3. CVD Event Rates With EvoMab Added to SOC vs SOC Alone, According to the Model
HeFH ASCVD ASCVD (Statin-Intolerant)
Health State EvoMab+SOC SOC Incre % Change EvoMab+SOC SOC Incre % Change EvoMab+SOC SOC Incre % Change
ACS 0.51 1.02 −0.51 −50 0.36 0.84 −0.48 −57 0.40 1.00 −0.60 −60
IS 0.11 0.23 −0.12 −51 0.06 0.14 −0.08 −58 0.07 0.18 −0.11 −61
HF 0.14 0.22 −0.08 −36 0.14 0.26 −0.11 −44 0.11 0.25 −0.14 −55
CHD death 0.51 0.68 −0.17 −25 0.25 0.41 −0.16 −39 0.25 0.43 −0.18 −43
IS deatha 0.19 0.14 0.05 33 0.11 0.10 0.01 10 0.13 0.12 0.01 11
Revascularization 0.49 1.14 −0.65 −57 0.40 1.03 −0.62 −61 0.38 1.02 −0.64 −63
Abbreviations: ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CI, conﬁdence interval;
CVD, cardiovascular disease; EvoMab, evolocumab; HeFH, heterozygous familial hypercholesterolemia; HF, heart failure; Incre, incremental; IS, ischemic
stroke; LDL-C, low-density lipoprotein cholesterol; SOC, standard of care.
aIS death was assumed to have an rate ratio of 1, because the rate ratio per 38.67-mg/dL LDL-C reduction was not statistically signiﬁcant (1.04; 99% CI:
0.77-1.41). The observed increases in CVD event rates occurred because of longer predicted survival with EvoMab+SOC.
Table 4. Predicted Total Costs, LYs, and QALYs for EvoMab Added to SOC vs SOC Alone
ICER, US$ Total Cost, US$ Total LY Total QALY
Population EvoMab+SOC SOC Alone Incre EvoMab+SOC SOC Alone Incre EvoMab+SOC SOC Alone Incre
HeFH 75 863 341 191 187 902 153 289 14.65 12.37 2.28 11.64 9.62 2.02
Medication 208 122 841 207 282
Fatal events 28 565 37 052 −8487
Nonfatal events 22 300 46 137 −23 837 0.46 0.96 −0.49 0.28 0.57 −0.29
Revascularization 18 565 44 638 −26 073
Long-term health states 63 638 59 234 4404 14.19 11.41 2.78 11.36 9.05 2.31
ASCVD 141 699 381 499 223 192 158 307 13.93 12.64 1.29 10.51 9.39 1.12
Medication 197 973 860 197 113
Fatal events 16 101 23 515 −7414
Nonfatal events 17 323 39 019 −21 696 0.36 0.81 −0.45 0.22 0.48 −0.26
Revascularization 16 685 43 082 −26 397
Long-term health states 133 418 116 716 16 702 13.57 11.83 1.74 10.29 8.91 1.38
ASCVD (statin-intolerant) 100 309 348 006 211 104 136 903 13.11 11.63 1.48 10.15 8.79 1.36
Medication 185 325 0 185 325
Fatal events 17 439 26 255 −8816
Nonfatal events 18 330 46 552 −28 222 0.38 0.97 −0.58 0.23 0.57 −0.35
Revascularization 15 906 43 699 −27 793
Long-term health states 111 007 94 597 16 409 12.73 10.66 2.06 9.92 8.21 1.71
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; EvoMab, evolocumab; CVD, cardiovascular disease; HeFH, heterozygous familial
hypercholesterolemia; ICER, incremental cost-effectiveness ratio; Incre, incremental; LY, life-year; QALY, quality-adjusted life-year; SOC, standard of care.
lifetime incremental LYs of 2.28, 1.29, and 1.48, as well as
QALYs of 2.02, 1.12, and 1.36 (Table 4).
The ICERs of evolocumab added to SOC vs SOC alone
were US$75 863/QALY gained in HeFH; US$141 699 in
ASCVD; and US$100 309 in ASCVD with statin intolerance.
All ICERs met the ACC/AHA intermediate value and WHO
cost-effectiveness thresholds.
Univariate Sensitivity Analyses
The ICER for evolocumab added to SOC vs SOC alone
in HeFH and ASCVD patients met the WHO very cost-
effective/cost-effective and ACC/AHA high/intermediate
thresholds under most sensitivity analysis assumptions in
the ASCVD population without statin intolerance and all
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of the assumptions in the HeFH and ASCVD with statin
intolerance populations (see Supporting Information,
Figure 1, in the online version of this article).
Probabilistic Sensitivity Analysis
The probability of evolocumab added to SOC being
cost-effective compared with SOC under the WHO and
ACC/AHAwillingness to pay thresholds was 100% for HeFH
and ASCVD with statin intolerance patients, whereas it
was 87% and 63%, respectively, for ASCVD patients (for
probabilities of acceptance under a range of willingness to
pay thresholds, see Supporting Information, Figure 2, in the
online version of this article).
Scenario Analyses
The ICER was 23% and 24% lower in the scenario analysis
using reduction in rates of CVD with evolocumab added to
SOC vs SOC alone from the open-label extension studies.
This result reflects a greater CVD event rate reduction
(33%) than the one observed in the CTTC statin meta-
analysis. All scenario analysis ICERs met the ACC/AHA
high/intermediate value and WHO very cost-effective/cost-
effective thresholds, except for the scenarios with no
LDL-C–lowering effect on HF rates and alternative discount
rate of 5% for costs and outcomes analyses in the ASCVD
population (neither ACC/AHA threshold; see Supporting
Information, Table 2, in the online version of this article).
Evolocumab added to SOC vs SOC alone met willingness
to pay thresholds at the following maximum annual costs:
ACC/AHA, US$24 300 in HeFH, US$14 800 in ASCVD,
and US$19 300 in ASCVD with statin intolerance; WHO,
US$26 400 in HeFH, US$16 000 in ASCVD, and US$20 800
in ASCVD with statin intolerance.
Discussion
The presented economic evaluation found that evolocumab
priced at an annual cost of US$14 139 added to SOC
vs SOC alone had ICERs of US$75 863 in patients with
HeFH and US$141 699 in those with ASCVD (US$100 309
in ASCVD with statin intolerance). These ICERs met the
WHO cost-effectiveness and ACA/AHA high/intermediate
value thresholds26,27 in all target populations. Sensitivity
analyses confirmed the robustness of the model results.
Scenario analyses in the ASCVD population and baseline
LDL-C >100mg/dL found that alternative assumptions
generally yielded ICERs meeting the ACC/AHA and WHO
thresholds.26,27
Although the medication cost was higher for evolocumab
than for statins, the greater LDL-C–lowering effects and
modeled reduction in CVD events among evolocumab-
treated patients determined the resulting cost-effectiveness
of the medication. The HeFH populations demonstrated
better cost-effectiveness than the ASCVD population, which
is consistent with the differences in baseline LDL-C
levels and particularly cardiovascular risk. The better cost-
effectiveness values with HeFH show the importance of
studying cost-effectiveness by specific population type.
Overall, our scenario analyses confirmed that changes in
major assumptions would likely lead to ICERs that meet
ACC/AHA and WHO thresholds. Notably, the scenario
using a post-hoc cardiovascular-event reduction from a
randomized open-label extension study9 of evolocumab
found a lower ICER than the base case (which used the
CTTC rate ratios3).
To the best of our knowledge, we present the
first published cost-effectiveness data on evolocumab,
though the Comparative Effectiveness Public Advisory
Council–Institute for Clinical and Economic Review
(CEPAC-ICER) has released a technology assessment32
of PCSK9 inhibitors. This report concludes that PCSK9
inhibition is not cost-effective with current annual costs
in the US societal context, and we concluded that
there was strong evidence of cost-effectiveness in the
US payer context. Several methodological differences
between the CEPAC-ICER report and our model should
be noted. The CHD Policy model used by CEPAC-ICER
underestimates the impact of single risk-factor interventions
(eg, cardiovascular risk), a limitation that was noted in
the original model publication.33 The CHD Policy model
was intended to model cardiovascular risk in the entire
US population not controlled on statins (age 35-74 years)
and not high-risk populations. A recent review article
included an analysis to externally validate the results from
the CHD Policy model.33 The results from the external
validation found in the Supporting Information in the online
version of this article demonstrate that the CHD Policy
model underestimated incidence of CHD by approximately
50%.34 The CEPAC-ICER report also does not account
for the elevated risk of CVD events among HeFH and
ASCVD patients. Other cost-effectiveness models of familial
hypercholesterolemia have incorporated this risk,35–37 as
we do in the present study.
Study Limitations
There are several limitations of our study.Our results should
be interpreted within the model assumptions; however, the
results of multiple sensitivity analyses did not significantly
affect our final conclusions. The LDL-C reductions used
in the model were based on short-term studies,6–8 and
there is very limited long-term data on evolocumab
specifically, or PCSK9 inhibitors generally. The potential
CVD event–lowering effect and harms of evolocumab added
to SOC have therefore not been established. If the clinical
benefit differs from that modeled in this study or significant
adverse events emerge, the cost-effectiveness modeling
results would be affected. A longer-term, CVD event–driven
study (NCT01764633) of evolocumab is ongoing, so we used
reductions per 38.67mg/dL of LDL-C reduction from the
CTTC meta-analysis of statin studies to predict impact of
LDL-C reduction on CVD event outcomes.3 The IMPROVE-
IT study4 suggests that LDL-C reduction using a nonstatin
may significantly reduce CVD-event risk with derived rate
ratio aligned with the CTTC findings, though there are
differing viewpoints about the clinical significance of the
observed reductions in IMPROVE-IT. Also, rate ratios from
the CTTC meta-analysis were used for acute health states
in which a statistically significant rate ratio was reported,
except for HF, for which the rate ratio was assumed to be
the same as ACS, because the literature on CVD event
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reduction with LDL-C reduction is not yet robust. We
assumed, however, no LDL-C–reduction impact onHF rates
for patients with recurrent HF.38–40 No LDL-C–lowering
effect on HF rates for any transitions was also tested in
a scenario analysis (see Supporting Information, Figure 1,
in the online version of this article). Finally, our analysis
and all conclusions derived from it are only applicable to
the HeFH and ASCVD populations with the risk profile
described in Table 1. The analysis is not generalizable to a
broader population with less severe disease.
Conclusions
When used in patients withHeFHor ASCVDwho are unable
to control LDL-C levels with maximally tolerated statins and
who remain at high risk, addition of evolocumab to SOC
may be cost-effective.
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